GENESIS-PHARMA
1.3.2024 09:38:30 CET | Business Wire | Press release
GENESIS Pharma, a regional biopharma company specialized in the commercialization of innovative medicines targeting severe and rare diseases in Central and Eastern Europe, announces an exclusive distribution agreement for the cancer medicine cemiplimab in Greece, Cyprus and Malta with Regeneron Ireland DAC. Regeneron Ireland DAC is a wholly owned subsidiary of Regeneron, a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.
Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. In the European Union, cemiplimab is indicated for adults as monotherapy treatment for certain patients with locally advanced or metastatic basal cell carcinoma (BCC), as monotherapy treatment for certain patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), as both monotherapy or in combination with chemotherapy for certain patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and as monotherapy treatment for certain patients with recurrent or metastatic cervical cancer.
The two companies will work to seamlessly complete the transition of all relevant commercialization activities by the second quarter of 2024.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “For more than 20 years our company has been committed to ensure patient access to innovative therapies for serious diseases in several European markets building upon a constantly growing network of partners that includes leading global biopharma companies. It is thus our honor to initiate a new agreement with Regeneron, a pioneering company committed to cutting-edge science, that further enhances our long-term expertise and focus on medicines targeting difficult-to-treat cancers.”
About GENESIS Pharma: GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies.
For more information, please visit www.genesispharmagroup.com or follow GENESIS Pharma on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301136761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Will Present New Evidence on Long-term Outcomes in Allergen Immunotherapy at EAACI 202611.6.2026 10:09:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, will present new clinical evidence and scientific advances in allergen immunotherapy (AIT) at the European Academy of Allergy and Clinical Immunology (EAACI) congress, taking place from June 12 to 15 in Istanbul, Turkey. The company will host a scientific symposium entitled “From Nobel Prize discovery to AIT clinical evidence: Shaping pathways to respiratory allergy remission.”Three leading international experts will explore how landmark breakthroughs in immunology have deepened our understanding of immune tolerance, presenting emerging data on remission and long-term outcomes in respiratory allergy. Together, these insights reinforce AIT’s disease-modifying potential and its growing role in personalised medicine. “EAACI 2026 is an exceptional forum for the global allergy community to exchange knowledge and advance the field. Stallergenes Greer is proud contribute to these conversations, bringing together world-leading experts in pur
NIPPON KINZOKU’s “FINE PIPE” Series Welded Drawn Pipes Outperforming Seamless Pipes11.6.2026 10:01:00 CEST | Press release
Featuring “High-Precision Inner Surface” Small-Diameter tubes and “FINE PEEK-ST” stainless steel and PEEK resin composite tubes NIPPON KINZOKU CO., LTD. (TOKYO:5491) (Headquarters: Minato-ku, Tokyo) has commercialized its “FINE PIPE” series *1, -welded drawn pipes that outperform traditional seamless pipes. By leveraging its unique expertise as a material manufacturer and proprietary processing technologies (welding, drawing, and annealing), the company delivers high-quality, eco-friendly, and cost-effective solutions. FINE PIPE is already widely adopted across various sectors, including automotive parts, measuring instruments, and industrial equipment, to meet the most demanding precision requirements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611874307/en/ In response to the growing demand for higher performance and faster processing in analytical and medical devices, NIPPON KINZOKU has developed two innovative pro
Comrade Trustee Services goes live with Smartstream’s Air, the AI reconciliation and data automation solution11.6.2026 09:55:00 CEST | Press release
Key Facts Comrade Trustee Services is live on Smartstream’s Air for automated reconciliations with fully integrated workflows. The implementation replaces highly manual, spreadsheet-driven processes and complex file handling with a single-click, straight-through AI-driven workflow. This will improve accuracy, control and operational efficiency. Processing time has been reduced from up to eight hours to under five minutes, with additional scalability for complex file types, formats and reconciliation logic. Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces that Comrade Trustee Services Limited (CTSL), trustee for the Defence Force Retirement Benefit Fund in Papua New Guinea, has gone live with Smartstream’s Air, the AI reconciliation and data automation solution – cutting processing times from eight hours to under five minutes. The go-live delivers a fully automated, straight-through reconciliation workflow, enabl
Wolters Kluwer enhances its Libra legal AI workspace in Italy by adding content specializations for One and integrating with Kleos11.6.2026 09:00:00 CEST | Press release
Libra by Wolters Kluwer integrates AI with authoritative, expert-generated content and operational workflows, supporting legal professionals across the entire workflow Wolters Kluwer Legal & Regulatory announced today new content and feature integrations in its legal AI workspace Libra by Wolters Kluwer for the Italian market. Customers will have access to additional expert-generated content in compliance, criminal law and tax law, and profit from the integration with Kleos, the cloud-based practice management solution for law firms. Designed to support the daily work of legal professionals, Libra by Wolters Kluwer combines advanced AI functionalities with trusted sources and authoritative, author-generated legal content. Within a single environment, it enables research, analysis and drafting activities based on reliable sources, while maintaining full control over results and quality. By integrating additional expert content from One, Wolters Kluwer’s leading legal research platform,
Pleo Announces New Agentic Capabilities, Changing the Face of Financial Management and Decision-Making11.6.2026 09:00:00 CEST | Press release
Pleo’s new agentic capabilities to let finance teams focus on strategic command, not admin These new agentic capabilities offer a clear path forward for finance leaders: especially when 63% say AI skills, training and confidence are severely lagging. Pleo, Europe's first and most trusted strategic finance platform, today announces a suite of AI agents that handle routine spend management autonomously, so finance leaders can focus on decisions rather than administrative tasks. Finance teams are under growing pressure: 45% of European companies say their current processes slow them down, and leaders describe approval workflows as so cumbersome they struggle to operate at the required speed. Meanwhile, 73% believe the future of finance teams and professionals depends on the comprehensive understanding and use of AI, yet 63% say AI skills, training and confidence are severely lagging. Pleo's agentic AI addresses this gap. Starting with beta testing in July, Pleo is moving toward a model wh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom